No registrations found.
ID
Source
Brief title
Health condition
Muscle mass growth; which can be related to sarcopenia
Sponsors and support
Intervention
Outcome measures
Primary outcome
Muscle protein synthesis
Secondary outcome
whole-body protein synthesis, breakdown, oxidation, and net balance, plasma amino acids, glucose and insulin, and plasma, L-[ring-13C6]-phenylalanine, L-[ring-13C6]-tyrosine, L-[3,5-2H2]-tyrosine enrichments
Background summary
An important determinant to maintain and/or increase skeletal muscle mass in rest and after (resistance) exercise is dietary protein intake. Especially with aging ingestion of high-quality dietary proteins is a strategy to counteract sarcopenia. In this regard, milk protein has been studied frequently and is considered as a high-quality protein source. However, little is known about other milk-derived protein sources such as quark. Therefore, the aim of the present study is to assess the capacity of quark to stimulate post-prandial and post-exercise skeletal muscle protein synthesis when compared to basal, post-absorptive muscle protein synthesis in young and older males.
Study objective
We hypothesize that the ingestion of quark will increase post-prandial muscle protein synthesis at rest in both young and older men. In addition, we hypothesize that exercise will augment the post-prandial muscle protein synthetic response to quark ingestion in both young and older men.
Study design
Muscle biopsies taken at -150, 0, and 240 min.
Intervention
Exercise and quark intake
Inclusion criteria
• Healthy males
• Age between 18 and 35 y or 65 and 85 y inclusive
• BMI between 18.5 and 30 kg/m2
Exclusion criteria
• Allergies to milk proteins
• Lactose intolerant
• Smoking
• Phenylketonuria
• Diabetes Mellitus (diagnosed, or fasting glucose >7.0 mmol/L, or HbA1c >6.5)
• Diagnosed GI tract disorders or diseases
• Arthritic conditions
• A history of neuromuscular problems
• Any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications).
• Use of certain anticoagulants (use of thrombocyte aggregation inhibitors such as acetylsalicylic acid and carbasalaatcalcium is permitted. Use of other thrombocyte aggregation inhibitors will be discussed with the responsible physician)
• Blood donation within 2 months of study initiation
• Hypertension (according to WHO criteria; >90/140 mmHg)
• Recent participation in amino acid tracer studies (less than 1 year ago)
• Physical activity (not training more than 3 times per week and no structured resistance training.)
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL8403 |
| Other | METC azM/UM : METC19-074 |